BeiGene begins Phase I trial of BGB-290 in China to treat solid tumours

US-based clinical-stage biopharmaceutical company BeiGene has begun its Phase I clinical trial of BGB-290 in China to treat advanced solid tumours.

Source: Drug Development Technology - December 22, 2016 Category: Pharmaceuticals Source Type: news